Kratom, Drug Scheduling, and the Opioid Crisis- Yale Medical School

Mason Marks, MD, JD discusses Mitragyna speciosa (kratom) and its potential to be categorized as a Schedule I controlled substance by the U.S. Drug Enforcement Agency. Dr. Marks is an attorney, legal scholar, and visiting fellow at Yale Law School's Information Society Project. This lecture was recorded on December 13, 2017 at Yale Medical School and was sponsored by the Yale Psychedelic Science Group and the Department of Psychiatry. Full lecture available here: https://www.youtube.com/watch?v=SLrtixosxGk Paper available on SSRN: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3065035 Blog post on kratom and the opioid crisis at Harvard Bill of Health: http://blogs.harvard.edu/billofhealth/2017/12/20/opioid-crisis-requires-evidence-based-solutions-part-2/ The views expressed in this presentation are not necessarily those held by Yale University or Yale Medical School and are not intended to constitute medical or legal advice.